# Advancing Postmenopausal Preventive Therapy

Study · id `cardio:ct-nct04103476` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04103476](<https://clinicaltrials.gov/study/NCT04103476>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT04103476

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 385 participants.

## Technical summary

Registry record NCT04103476. Randomized; quadruple masking; primary purpose treatment. Start 2021-04-13 (actual); primary completion 2026-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 385 participants (enrolled count; ClinicalTrials.gov record NCT04103476, source copy `cardio:ctgov-nct04103476-2024-12-05`, retrieved 2026-10-31)
- Started: 2021-04-13 (actual) (ClinicalTrials.gov record NCT04103476, source copy `cardio:ctgov-nct04103476-2024-12-05`, retrieved 2026-10-31)
- Primary completion: 2026-10-31 (anticipated) (ClinicalTrials.gov record NCT04103476, source copy `cardio:ctgov-nct04103476-2024-12-05`, retrieved 2026-10-31)
- Completion: 2026-12-31 (anticipated) (ClinicalTrials.gov record NCT04103476, source copy `cardio:ctgov-nct04103476-2024-12-05`, retrieved 2026-10-31)
- Countries: United States (ClinicalTrials.gov record NCT04103476, source copy `cardio:ctgov-nct04103476-2024-12-05`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04103476-2024-12-05`, retrieved 2026-10-31)

## The registry's words

- Brief title: Advancing Postmenopausal Preventive Therapy
- Acronym: APPT
- Condition: Atherosclerosis
- Condition: Cognitive Decline
- Intervention (Combination product): Oral bazedoxifene 20 mg / conjugated estrogens 0.45 mg
- Intervention (Other): Placebo
- Lead sponsor: University of Southern California
- Lead sponsor class: OTHER
- Collaborator: National Institute on Aging (NIA)
- Collaborator class: NIH

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry lists this organization as the lead sponsor: University of Southern California (`cardio:org-university-of-southern-california`)
- Registry lists this organization as a collaborator: National Institute on Aging (`cardio:nia`)

## Provenance

Content hash: 284345e10bceb8bda03c806559f5386a423e4eac7ca014b086bb24728d13d08e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
